The randomized placebo-controlled trial on fluoxetine combined with olanzapine in treating major depression
- VernacularTitle:氟西汀合用小剂量奥氮平治疗重度抑郁症的随机对照试验
- Author:
Wei QU
;
Yuanyuan QIN
- Publication Type:Journal Article
- Keywords:
fluoxetine;
olanzapine;
major depression
- From:Journal of Third Military Medical University
2003;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and effective time of low dosage of olanzapine combined with fluoxetine in treatment of major depression. Methods A total of 53 patients who suffered from major depression diagnosed according to CCMD-3 and the score of Hamilton rating scale for depression (HAMD) over 28, were randomly divided into 2 groups: alprazolam group (0.4 mg alprazolam, 2/d and 20 mg fluoxetine, 1/d), olanzapine group (2.5 mg olanzapine, 1/d, and 20 mg fluoxetine, 1/d). The treatment period lasted six weeks and the subjects were evaluated by using HAMD and HAMA at week 1, 2, 4, 6. The effective time was estimated by decreasing rate of the scale of HAMD and the amelioration of sleep disturbance and anxiety/somatization in HAMD were observed before and during the treatment. Results The therapeutic effects in olanzapine group at week 1 were observed with the apparent rate of 67%. The scores of HAMD and HAMA in olanzapine group were obviously lower than those in alprazolam group at each time point. The sleep disturbance and anxiety/somatization of the patients in olanzapine group improved significantly as compared with those in alprazolam group. Conclusion Fluoxetine combined with olanzapine is a fast and effective method to treat major depression.
